

PROVIDER QUICK POINTS

PROVIDER INFORMATION



October 11, 2023

Update: Medical Drug Update for Tofersen (Qalsody), Delandistrogene Moxeparvovec (Elevidys), and Donislecel (Lantidra)

On April 12, 2023, Provider Quick Point [QP34-23](#) communicated the addition of **tofersen (Qalsody)** to the Medical Drug Evaluation Process List under Blue Cross and Blue Shield of Minnesota (Blue Cross) medical policy II-174, upon approval by the U.S. Food and Drug Administration (FDA). The drug was approved by the FDA on April 25, 2023. Effective October 2, 2023, there will be a drug-specific Blue Cross medical policy for tofersen (policy II-280). The drug will be removed from medical policy II-174 and the Medical Drug Evaluation Process List and addressed under medical policy II-280.

On June 14, 2023, Provider Quick Point [QP48-23](#) communicated the addition of **delandistrogene moxeparvovec (Elevidys)** to the Medical Drug Evaluation Process List under Blue Cross and Blue Shield of Minnesota (Blue Cross) medical policy II-174, upon FDA approval. The drug was approved by the FDA on June 22, 2023. Effective December 4, 2023, there will be a drug-specific Blue Cross medical policy for delandistrogene moxeparvovec (policy II-284). The drug will be removed from medical policy II-174 and the Medical Drug Evaluation Process List and addressed under medical policy II-284.

On June 9, 2021, Provider Quick Point [QP49-21](#) communicated the addition of **donislecel (Lantidra)** to the Medical Drug Evaluation Process List under Blue Cross and Blue Shield of Minnesota (Blue Cross) medical policy II-174, upon FDA approval. The allogeneic pancreatic islet cellular therapy was approved by the FDA on June 28, 2023. Effective December 4, 2023, donislecel will be added to Blue Cross medical policy for Islet Cell Transplantation and Cellular Therapy (policy IV-09). Donislecel will be removed from medical policy II-174 and the Medical Drug Evaluation Process List and addressed under medical policy IV-09.

Products Impacted

Subscribers with coverage through commercial health plans (excluding Federal Employee Program (FEP) which has separate requirements).

Reminder Regarding Medical Policy Updates & Changes:

Medical Policy changes are communicated in the Upcoming Medical Policy Notifications section of the Blue Cross Medical and Behavioral Health Policy website. The Upcoming Policies section lists new, revised, or inactivated policies approved by the Blue Cross Medical and Behavioral Health Policy Committee and are effective at minimum 45 days from the date they were posted. To access the website:

- Go to <https://www.bluecrossmn.com/providers/medical-management>
- Select "See Medical and Behavioral Health Policies" then click "See Upcoming Medical and Behavioral Health Policy Notifications."

Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.

QP81-23

Distribution: [bluecrossmn.com/providers/forms-and-publications](https://www.bluecrossmn.com/providers/forms-and-publications)